818 related articles for article (PubMed ID: 18813886)
1. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
3. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
4. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
5. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease.
Bárány P; Müller HJ
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv10-iv18. PubMed ID: 17526545
[TBL] [Abstract][Full Text] [Related]
6. [Anemia: guidelines comparison].
Del Vecchio L
G Ital Nefrol; 2009; 26(6):686-94. PubMed ID: 19918751
[TBL] [Abstract][Full Text] [Related]
7. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
Strippoli GF; Craig JC; Manno C; Schena FP
J Am Soc Nephrol; 2004 Dec; 15(12):3154-65. PubMed ID: 15579519
[TBL] [Abstract][Full Text] [Related]
8. [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4].
Choukroun G; Renou M; Lecaque C; Jauréguy M
Nephrol Ther; 2011 Feb; 7(1):2-9. PubMed ID: 21216683
[TBL] [Abstract][Full Text] [Related]
9. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
10. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
11. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
Spiegel DM; Khan I; Krishnan M; Mayne TJ
Am J Kidney Dis; 2010 Jan; 55(1):113-20. PubMed ID: 19932539
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.
Kliger AS; Fishbane S; Finkelstein FO
Clin J Am Soc Nephrol; 2012 Feb; 7(2):354-7. PubMed ID: 22266571
[TBL] [Abstract][Full Text] [Related]
13. [Anemia as a risk factor for CKD and CVD].
Tsuruya K; Hirakata H
Nihon Rinsho; 2008 Sep; 66(9):1786-93. PubMed ID: 18788410
[TBL] [Abstract][Full Text] [Related]
14. An economic evaluation of erythropoiesis-stimulating agents in CKD.
Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
[TBL] [Abstract][Full Text] [Related]
15. The optimal hemoglobin in dialysis patients- a critical review.
Singh AK; Fishbane S
Semin Dial; 2008; 21(1):1-6. PubMed ID: 18251947
[TBL] [Abstract][Full Text] [Related]
16. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
17. [The need to revise the hemoglobin threshold value in the German Quality Assurance Directive for Dialysis].
Maurin N
Dtsch Med Wochenschr; 2012 Jan; 137(3):90-3. PubMed ID: 22135182
[TBL] [Abstract][Full Text] [Related]
18. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
20. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]